loading page

Role of TDM-based dose adjustments for major taxane anticancer drugs
  • +1
  • Marsilla Muth,
  • Francis Ojara,
  • Charlotte Kloft,
  • Markus Joerger
Marsilla Muth
Kantonsspital Sankt Gallen
Author Profile
Francis Ojara
Free University of Berlin
Author Profile
Charlotte Kloft
Free University of Berlin
Author Profile
Markus Joerger
Kantonsspital Sankt Gallen
Author Profile

Abstract

Purpose: The classical taxanes (paclitaxel, docetaxel), the newer taxane cabazitaxel and the nanoparticle-bound nab-paclitaxel are among the most widely used anticancer drugs. Still, the optimal use and the value of pharmacological personalization of the taxanes is still controversial. Methods: We give an overview on the pharmacological properties of the taxanes, including metabolism, pharmacokinetics-pharmacodynamic relations and aspects in the clinical use of taxanes. The latter includes the ongoing debate on the most effective and safe regimen, the recommended initial dose, and pharmacological dosing individualization. Conclusions: The taxanes are among the most widely used anticancer drugs in patients with solid malignancies. Despite their longtime use in clinical routine, the optimal dosing strategy (weekly versus 3-weekly) or optimal average dose (cabazitaxel, nab-paclitaxel) has not been fully resolved, as it may differ per tumor entity and line of treatment. The value of pharmacological individualization of the taxanes (TDM, TCI) has partly been explored for 3-weekly paclitaxel and docetaxel, but remains mostly unexplored for cabazitaxel and nab-paclitaxel at present.

Peer review status:IN REVISION

19 Apr 2020Submitted to British Journal of Clinical Pharmacology
21 Apr 2020Submission Checks Completed
21 Apr 2020Assigned to Editor
29 Apr 2020Reviewer(s) Assigned
08 Jul 2020Review(s) Completed, Editorial Evaluation Pending
19 Jul 2020Editorial Decision: Revise Major
10 Sep 20201st Revision Received
18 Sep 2020Assigned to Editor
18 Sep 2020Submission Checks Completed